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ABSTRACT
Recently, clinical pathway (CP) has been used to reduce the variation and
optimise the ST-elevation myocardial infarction (STEMI) process of care.  The
evaluation domains of STEMI CP quality remain inconsistent information. The aim
of this research is to develop an evaluation model to guide the decision making on
the optimal STEMI clinical pathways content and design.  A qualitative and
quantitative (mixed method) was used to generate and analyse the data of this
research.  First, the initial research STEMI clinical pathway concept has been
developed from theory and practice. Second, the concept was tested in subsequent
questionnaires distributions (pilot and actual study).  Third, a clinical pathway
quality evaluation model for STEMI (STEMICPQ) has been proposed and then
assessed by structural equation modelling (SEM) path analysis using smart PLS
version 3.0 software.  Fourth, the sensitivity and specificity of the proposed model
were tested in comparison to three quality criteria performance in 138 retrospective
trial records. The results of the two stages questionnaire demonstrated an agreement
on the items grouping and classification by the experts on most of the items of the
questionnaire.  A total of 186 responses from the second questionnaire have been
returned involving 84 specialists and 76 nurses.  The items content validity index
(ICVI) is greater than 80%, and the construct reliability (Cronbach Alpha) is 0.85.
This research proposes a model consisted of three STEMI CP quality domains
(Design and Content, Process and Activity, and Outcome and Variance) with total 30
items and 60 sub-items and proven its ability to evaluate the quality of STEMICP.
The STEMICPQ model validation results have established strong composite
reliability, predictive relevance and power of explanation. The hypothesis testing
revealed that the outcome and variance is a strong predictor of the STEMI clinical
pathway quality with path coefficient (β) = 0.65, t statistics (t) = 17.4 and item
loadings significant (p) = 0.000. From a retrospective CP trial study, the overall
predictive power of the STEMICPQ shows high sensitivity of 0.915, specificity of
0.942 and area under the curve accuracy (AUC) of 0.93 in comparison to the length
of stay criterion (LOS) of STEMI patients.  As a conclusion, this model revealed
suitable to be implemented in the health care institution to improve the quality of
healthcare for STEMI patients. Also, it provides the experts with a valid, feasible
and practical decision-making tool to be used in the hospitals during the design stage
of STEMI CP. This work does not cover the organisational or human factors.
vABSTRAK
Kebelakangan ini, laluan klinikal (CP) telah digunakan untuk mengurangkan
perubahan dan mengoptimumkan proses penginfarkan miokardium elevasi segmen ST
(STEMI). Kajian ini bertujuan untuk membentuk satu model penilaian yang optimum
sebagai panduan membuat keputusan ke atas isi kandungan aliran klinikal STEMI dan
reka bentuk. Kaedah campuran kualitatif dan kuantitatif telah digunakan untuk menjana
dan menganalisis data kajian ini. Pertama, konsep tinjauan semula dilakukan bagi teori
yang sedia ada (ulasan peninjauan semula) dan amalan perubatan (temu duga pakar-
pakar dan analisis dokumen STEMI CP). Penyelidikan awal kajian telah dilaksanakan
dalam fasa ini dan telah diuji melalui pengagihan borang soal selidik (kajian rintis dan
sebenar) yang seterusnya pada fasa yang kedua.  Ketiga, model penilaian kualiti aliran
klinikal STEMI (STEMICPQ) telah dibangunkan seterusnya dinilai oleh analisis laluan
permodelan persamaan struktur (SEM) dengan menggunakan perisian PLS pintar versi
3.0. Keempat, kepekaan dan kekhususan model yang dicadangkan telah diuji secara
perbandingan dengan tiga kriteria kualiti yang telah ditaksir dalam 138 rekod kajian
retrospektif. Keputusan daripada dua peringkat soal selidik menunjukkan persetujuan
oleh pakar-pakar pada kebanyakan perkara dalam borang soal selidik dari segi
pengumpulan dan pengelasan perkara. Sejumlah 186 maklumbalas dari borang soal
selidik kedua telah diterima yang melibatkan 84 orang pakar dan 76 orang jururawat.
Indeks kesahan isi kandungan perkara (ICVI) ialah melebihi 80% dan keutuhan binaan
(Cronbach Alpha) ialah 0.85. Kajian ini mengusulkan model yang terdiri daripada ‘tiga’
bidang kualiti STEMI CP (Reka Bentuk dan Kandungan, Proses dan Aktiviti serta Hasil
dan Perbezaan) dengan sejumlah 30 perkara dan 60 sub-perkara dan dibuktikan
kebolehannya untuk menilai kualiti STEMI CP. Keputusan kesahan model STEMICPQ
telah mewujudkan keutuhan komposit yang kukuh dan ramalan yang relevan dan kuasa
yang penting. Hasil dari pengujian hipotesis mendapati keputusan dan perbezaan adalah
peramal yang kukuh bagi kualiti aliran klinikal STEMI dengan koefisien laluan (β) =
0.65, statistik t (t) =17.4 dan ketaraan beban perkara (p) = 0.000. Dari kajian percubaan
CP secara retrospektif, kuasa peramalan keseluruhan STEMICPQ menunjukkan
kepekaan 0.915, kekhususan 0.942 yang tinggi dan kawasan di bawah lengkungan
ketepatan (AUC) 0.93 kriteria berbanding tempoh penginapan (LOS) pesakit-pesakit
(STEMI). Kesimpulannya, model ini didapati sesuai untuk dilaksanakan dalam institusi
penjagaan kesihatan untuk meningkatkan kualiti penjagaan kesihatan untuk pesakit
STEMI. Selain itu, ia juga menyediakan alat membuat keputusan yang sah, boleh
dilaksanakan dan praktikal kepada pakar-pakar untuk digunakan di hospital semasa
peringkat reka bentuk STEMI CP. Kerja ini tidak melibatkan faktor-faktor organisasi
atau faktor manusia.
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CHAPTER 1
INTRODUCTION
1.1 Research Background
ST-elevation myocardial infarction (STEMI) disease happens due to the full
thickness damage of the heart muscle (Thygesen et al., 2012). STEMI continues to be
one of the most common reasons for hospitalisation worldwide (O’Gara et al., 2013
and Hall et al., 2016). Furthermore, it continues to contribute to 80% of the mortality
rate worldwide STEMI contribute to 25-40% of the overall cardiovascular disease
(CVD) morbidity in Malaysia (World Health Organisation, 2014) (Figure 1.1). As
simplified in Figure 1.2, the progress of the myocardial infarction (MI) after blockage
of the coronary artery leads to oxygen deprivation causing heart muscle deaths and
will be manifested by ECG St-segment elevation.
2Figure 1.1 (a) Percentage of the total death by age and sex in Malaysia (WHO
Malaysia non-communicable disease country profile, 2014). (b) Myocardial infarction
mortality worldwide (World Health Organization, 2016)
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Figure 1.2 (a) Plaque formed on the wall of the arteries causing (Anatomy Medicine,
2016). (b) Acute myocardial infarct and (c) ECG ST-segment elevation (Emergency
Medicine Ireland, 2016)
The management of STEMI depends on standard diagnostic and therapeutic
measures following the clinical practice guidelines (CPGs).  CPGs are statements
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3reached after expert’s consensus and rigorous review of the evidence from randomised
trials.  CPGS considered as the source for optimal care and improve the quality of
patient care (Mehta, 2002). For example, Malaysia STEMI clinical guidelines
(Robaayah Zambahari et al., 2014) changed the death rate among STEMI patients
minimally and similarly worldwide.  Variations in the process of care remain as a
significant quality issue in health care, and the patients may not yet receive the optimal
care (Steg et al., 2012; Chan et al., 2016 and De Boer and Zijlstra, 2015). Various
research studies have attributed that to the poor CPGs compliance due to its subjective
nature and lengthy statements (Chan et al., 2015; Hansen et al., 2015; Lelgemann and
Ollenschlager, 2006 and Lip et al., 2015).
The drawback in STEMI management as mentioned above, lead to the use of
“Clinical pathway” (CP) in health care to ease the use of CPGs and enhances adherence
to its standards (Young, 2002). Clinical pathway (CP) functions as an operational tool
to integrate the clinical evidence to the practice and standardise the process of care.
Clinical pathway  defined as “a complex intervention for the mutual decision-making
and organisation of care processes for a distinct group of patients during a well-defined
period.” (Vanhaecht, K. et al., 2007). Queensland health clinical pathways board
(2012) defined clinical pathway as “multidisciplinary management plans, which
identify an appropriate sequence of clinical interventions, timeframes, milestones and
expected outcomes for specific patient group”.
Clinical pathways evolved as a solution for the variation in care issues improve
efficiency and effectiveness.  Consequently, clinical pathway enhances the quality of
care process and support different diseases.  Furthermore, it alleviates the guideline
limitations such as lengthy content, variances in actions and procedures (Geleris and
Boudoulas, 2011). Clinical pathway has adopted important features from the clinical
guideline, the ‘easy to access’ feature from protocols, timeline and logical order from
the algorithm.  Besides, it is unique by having a focus on the quality and coordination
of care. Indeed, CPs has been mainly attracting attentions to standardise the process
of care and to ensure benefits for the patient and hospitals (Woolf et al., 1999).
4A clinical pathway is a complex intervention aims to assist in several functions
such as decision-making, an organisation of care processes, and implementation of
evidence and integrate quality indicators into clinical practice.  Also, it helps in
continuous monitoring and data evaluation (variance analysis) and potentially reduces
healthcare costs. (Lawal et al., 2016; Lodewijckx et al., 2012; Marrie et al., 2000;
Rotter et al., 2010; Rotter et al., 2012 and Vanhaecht and Witte, 2007).
Clinical pathway development pass through several steps life cycle using ‘plan,
do, study and act’ (PDSA) theory (Vanhaecht et a.l, 2007).  It starts by identifying the
need to the clinical pathway and end with implementation and analysis as illustrated
in Figure 1.3 (Heiden, 2012). The life cycle of the clinical pathway had an average of
1-3 years according to National Health service England (NHS) (2011) and could be
shortened to only one year depending on the management process (Vanhaecht et al.,
2007). Figure 1.3 shows the life cycle of STEMI clinical pathway from development
to redesign according to PDSA cycle.
Figure1.3Depict the clinical pathway lifecycle integrated with PDSA theory modified
from Queensland health clinical pathways (2005)
5The development of the clinical pathway depends on the consensus of the
experts in the field; each organisation (hospital) has its clinical pathway based on the
standard operation procedures (SOP) and the guideline for the health ministry’s
publications of the regions as a source for optimal care. The patients are the main
target for the clinical pathway usage, and it is proofed to improve patient outcomes,
safety, and optimise the use of clinical resources (Jernberg et al., 2011and Jollis et al.,
2012).
However, the current literature evidence show suboptimal adherence to clinical
pathway and variability in the quality of care (Lawal et al., 2016). The quality
indicators description in the guidelines is missing in most of the guidelines and several
factors lead to variation in clinical pathway design (Coffey et al., 2005 and Coffey et
al., 1992). De Boer and Zijlstra (2015) explained that the quality should not be
measured using only the time as an indicator to improve the outcome or the
performance of physicians, but presenting the best treatment options available to the
patient should also be considered as an indicator of success.
Various quality indicators under different themes do exist as highlighted by
Rogers (2015).  However, it becomes difficult to decide the most appropriate indicators
for the purpose of measurement. For example, the existing research focuses on the
outcome as an indicator of CP quality with less focus on the other quality attributes
such as design and process. Nevertheless, the study by Mallock and Braithwaite
(2005) has highlighted some criteria to select the core component of the clinical
pathway. Also, Ovretveit (2010), Panella et al. (2003) and Hamilton et al. (2008)
considered the involvement of the clinicians as a major factor in the development of
clinical pathway.  There is variation in the clinical pathway design due to the variability
in concepts, methods and groups responsible for the design beside the existence of
competing pathways among specialist and the hospitals (Aeyels et al., 2014; Chatterjee
and Joynt, 2014 and Demartino and Larsen, 2012).
61.2 Problem Statement
The variation in the process of care represents a serious quality issue which has
been standardised by the clinical pathway.  However, there are variations in STEMI
CP development and evaluation methods.  The current CPs evaluations tools would
usually measure different components from various aspects, various domains and
consider different outcome (Audimoolam et al., 2005; Aziz et al., 2012 and Van Herck
et al., 2010).
Furthermore, it is not clear whether the STEMI CP evaluation tools or models
exist and if any, are they suitable to evaluate the STEMI CP quality or not. In practice,
when experts decide to choose the best evidence to include in the CP, a revision of
many publications needs to be ensured.  This difficulty attributed to the variability in
CPs definitions concepts and functions.  Consequently, the development of clinical
pathway depends on the consensus of the experts in the field, guidelines and each
hospital has its designed clinical pathway.  This discrepancy added to the sources of
variation in care as each hospital will have a different plan with no standard for
designing the STEMI CPs. Also, there is a lack of standardisation of ST-elevated
myocardial infarction pathway documents (Aeyels et al., 2014; Mallock and
Braithwaite, 2005).
Moreover, in the existing literature, most of the studies have been looking at
the implementation aspect of the clinical pathway with pre-post CP implementation
comparison to examine the effect of the CPs on the improvement of the outcome.
However, little if any of these studies only focused on the first planning stage of the
CPs. There are weak methodological designs in most of the current CP development
studies lead to an indefinite evidence regarding the clinical pathway effectiveness and
consequently weak CP design quality (El Baz et al., 2007).
7From the aforementioned issues, the elements and the component of the
optimal STEMI clinical pathway that could make it more practical and keep its quality
perspective are still lacking with lack in developments guidance and variability in
evaluation methods.  Thus, it has become essential for the clinical pathway users to
have a tool that could measure CP information quality and provides direction to what
should be improved in clinical pathway and provide quick suggestions effectively.
This contribution would ultimately save time and efforts of trying different options
and plans with no definite result.
1.3 Research Objectives
The focal aim of this research was to develop STEMI CP Evaluation tool to
assist in decisions making on the best STEMI clinical pathway design to be
implemented for high quality and optimal patient care. Specifically, the objectives of
this research are:
1. To investigate the evidence on the STEMI clinical pathway evaluation
methods.
2. To identify the essential components of the STEMI clinical pathway that
contribute to optimal STEMI patient care as a base for an evaluation tool for
the STEMI clinical pathway quality.
3. To develop and validate a STEMI clinical pathway quality evaluation model.
81.4 Research Scope and Limitations
This research addresses STEMI clinical pathway. Besides, three quality
dimensions for the STEMI clinical pathway quality characteristics (‘Design and
Content’, ‘Process Medication and activities’ and Outcome and Variances) have been
determined and tested: Yet, in this research the organisational and managerial
dimensions were beyond the scope.
The primary intervention of this research was on the stage of design and
content decision by providing a decision-making tool to predict the quality of the
STEMI CP design before its implementation.  This research focuses mainly on
providing simple, reliable and optimal STEMI clinical pathway evaluation model that
could be used during the by the experts and benefit the patients.
Two volunteered hospitals in Kuala Lumpur Malaysia, and Jakarta Indonesia
that has the clinical pathway with at least one trial run in the hospital made the primary
cohort for study besides the randomises online survey recruitments. The second was
the scope of the study as the study only focused on STEMI patients.  Other diseases
could be considered in future research. Moreover; the research was limited to
developing a model and using structural equation modelling (SEM) and partial least
square regression (PLS) as well as to prove its validity by the use by experts and
retrospective trial evaluation study.  The time and context of this research restricted
the developed model.
One practical limitation was the type of respondents (STEMI and CP experts),
which is essential to perform a larger size for this research. Their busy schedules and
difficulties in reaching them hinder the sample size. The research was limited to
experts’ opinion and reviews using semi-structured interviews and survey.  Consents
and ethical approval constrained the approach and sample size.  These responses used
to establish the STEMI CP quality evaluation model in an iterative way. Another
9practical limitation was the volume of data produced from the evidence synthesis and
the rating by the experts, and finally, the quality of clinical pathway has been seen
previously as difficult to be measured. The additional practical limitation is the
changing evidence according to the latest guidelines could not be claimed under this
study as a revision for the newest evidence for the process and medications still needed.
1.5 Research Significant and Contributions
The current research study extends our knowledge of clinical pathway
properties and the domains of qualities.  The current finding adds to the growing body
of literature by merging the quality indicator measures with the CP general
characteristics to quantify the quality of STEMICP. The proposed STEMICPQ model
would work as a base for future research where other dimensions of quality could be
integrated and improved.
1.5.1 Theoretical Implications
Although the current study is based on a small group of respondents the study
suggests a model with predictive power and accuracy of 85%.  It also contributes to a
new understanding of the sub-constructs used to evaluate STEMI clinical pathway and
a tool for measuring the STEMI clinical pathway quality in healthcare that could be
used to assist in decision making. In general, this research contributes to the
knowledge by adding information on the characteristics of the STEMI clinical pathway
and covers the gap between the result of the literature reviews and the empirical
studies.
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This study is one of the scarce that covered the clinical pathway in a modeling
approach and bringing the macro quality dimensions to the clinical pathway class
concept.  That contributes to enhancing the research viewpoint in this STEMI CP
specific field.  This study also contributes by identifying the elements of STEMI CP
that mostly contribute to the CP quality and also identified the association between
three essential characteristics of the clinical pathway. The significant of this research
to the medical field is the details method that has been used for creating the optimal
criteria of STEMI clinical pathway.
1.5.2 Practical Implications
Considering the three quality domains in this study the quality is possible to be
measured by the experts themselves which is different than auditing. The practical
significance of this research can be brief in the following points:
 Healthcare quality implications: It is evident that the manner that any tool is
designed would affect its performance.  The developed model in this study is
unique in considering the quality domains according to the CP content, process
and outcome.  And the proposed criteria and component are unique to provide
guidance in the selection of the best STEMI CP design.
 Healthcare cost implications: The life cycle of the clinical pathway is long;
therefore, to avoid the waste of time and effort that may occurred in the time
of trials and implementation, this research STEMICPQ model is proposed to
be used them for decision making before implementation.  That could assist
the users before they deploy the clinical pathway and give an insight on how
good or bad is the STEMI clinical pathway design and reduce the cost of faulty
trials.
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 Procedural implications: Simple, user-friendly scoring computer based tool for
the STEMI CP criteria has been proposed.  The model is suitable for decision
making and would also easy for the expert’s work.  Although the design of
clinical pathway in many settings follows the plan- Do-Study-Act (PDSA)
cycle which is a branch of management’s theory, the clinical decision makers
do not use the measurement techniques employed in the management’s field.
 This work has combined both.  The tool in this study would resolve the tension
during the revision of all the publications before the design of clinical pathway.
I believe that this research would improve the clinical pathway user’s view on
the analytic approach and modelling techniques that may help in advancing the
research in this area and encourage the improvement of this field.
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